Kardigan, Inc.(KARD)

Biotechnology · Princeton, NJ

$14.19-1.05 (-6.89%)

Delayed quote: Oct 6, 2026, 12:10 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T16:12:43.065Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:12:43.065Z.

Quote observation: 2026-10-06T16:10:16.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,267,722,127
Total debt · period ending 2026-06-30: 13,347,000
Cash · period ending 2026-06-30: 384,005,000
TTM operating income · period ending 2026-06-30: N/A

FMP input reference: 6dd2a4984e4340952b62e9ecd156f35eed99e3c78779d37ae6f95d3f5c845125

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KARD EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

KARD Competitors' EV/EBIT Ratio

KARD

Kardigan, Inc.

Current

Market Cap

$1.27B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ORIC

ORIC Pharmaceuticals, Inc.

vs KARD

Market Cap

$1.24B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OMDA

Omada Health

vs KARD

Market Cap

$1.23B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRON

Cronos Group Inc.

vs KARD

Market Cap

$1.22B

EV/EBIT Ratio

59.84x

TTM Avg

63.01x

3Y Avg

63.01x

5Y Avg

63.01x

MNKD

MannKind Corporation

vs KARD

Market Cap

$1.21B

EV/EBIT Ratio

192.16x

TTM Avg

76.16x

3Y Avg

60.11x

5Y Avg

60.11x

INNV

Innovage Holding Corp.

vs KARD

Market Cap

$1.22B

EV/EBIT Ratio

19.07x

TTM Avg

131.59x

3Y Avg

131.59x

5Y Avg

72.61x

DRTS

Alpha Tau Medical Ltd

vs KARD

Market Cap

$1.32B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OMER

Omeros Corporation

vs KARD

Market Cap

$1.35B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

vs KARD

Market Cap

$1.36B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DMRA

Damora Therapeutics, Inc.

vs KARD

Market Cap

$1.17B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Kardigan, Inc. (KARD)	$1.27B	N/A	N/A	N/A	N/A
ORIC Pharmaceuticals, Inc. (ORIC)vs ›	$1.24B	N/A	N/A	N/A	N/A
Omada Health (OMDA)vs ›	$1.23B	N/A	N/A	N/A	N/A
Cronos Group Inc. (CRON)vs ›	$1.22B	59.84x	63.01x	63.01x	63.01x
MannKind Corporation (MNKD)vs ›	$1.21B	192.16x	76.16x	60.11x	60.11x
Innovage Holding Corp. (INNV)vs ›	$1.22B	19.07x	131.59x	131.59x	72.61x
Alpha Tau Medical Ltd (DRTS)vs ›	$1.32B	N/A	N/A	N/A	N/A
Omeros Corporation (OMER)vs ›	$1.35B	N/A	N/A	N/A	N/A
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.36B	N/A	N/A	N/A	N/A
Damora Therapeutics, Inc. (DMRA)vs ›	$1.17B	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

KARD EV/EBIT Ratio Metrics

KARD Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics